1932

Abstract

Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline alterations in the mismatch repair genes and is the most common etiology of hereditary colorectal cancer. While Lynch syndrome was initially defined by the clinical Amsterdam criteria, these criteria lack the sensitivity needed for clinical utility. This review covers the evolution of screening for Lynch syndrome from the use of tumor microsatellite instability and/or somatic alterations in mismatch repair protein expression by immunohistochemistry to the newest methods using next-generation sequencing. Additionally, it discusses the clinical implications of the diagnosis of Lynch syndrome as it affects cancer therapeutics and the role of screening in noncolorectal Lynch-associated cancers. As molecular oncology continues to evolve, it is crucial to remain current on the increasing complexity of Lynch syndrome diagnostics and treatment options.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-genom-083118-015406
2019-08-31
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/genom/20/1/annurev-genom-083118-015406.html?itemId=/content/journals/10.1146/annurev-genom-083118-015406&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T et al. 2018. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer 124:3145–53
    [Google Scholar]
  2. 2.
    Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R et al. 2006. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 354:2751–63
    [Google Scholar]
  3. 3.
    Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T et al. 2009. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin. Genet. 75:141–49
    [Google Scholar]
  4. 4.
    Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL et al. 2012. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J. Clin. Oncol. 30:1058–63
    [Google Scholar]
  5. 5.
    Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M et al. 2009. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27:1814–21
    [Google Scholar]
  6. 6.
    Bessa X, Alenda C, Paya A, Alvarez C, Iglesias M et al. 2011. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. J. Clin. Oncol. 29:3374–80
    [Google Scholar]
  7. 7.
    Boland CR, Goel A. 2010. Microsatellite instability in colorectal cancer. Gastroenterology 138:2073–87.e3
    [Google Scholar]
  8. 8.
    Buchanan DD, Rosty C, Clendenning M, Spurdle AB, Win AK 2014. Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). Appl. Clin. Genet. 7:183–93
    [Google Scholar]
  9. 9.
    Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM et al. 2014. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J. Clin. Oncol. 32:90–100
    [Google Scholar]
  10. 10.
    Catasús L, Bussaglia E, Rodríguez I, Gallardo A, Pons C et al. 2004. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 35:1360–68
    [Google Scholar]
  11. 11.
    Cenin DR, Naber SK, Lansdorp-Vogelaar I, Jenkins MA, Buchanan DD et al. 2018. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. J. Gastroenterol. Hepatol. 33:1737–44
    [Google Scholar]
  12. 12.
    Chen S, Wang W, Lee S, Nafa K, Lee J et al. 2006. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296:1479–87
    [Google Scholar]
  13. 13.
    Cohen SA, Laurino M, Bowen DJ, Upton MP, Pritchard C et al. 2016. Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. Cancer 122:393–401
    [Google Scholar]
  14. 14.
    Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA et al. 2016. Frequent PIK3CA mutations in colorectal and endometrial tumors with 2 or more somatic mutations in mismatch repair genes. Gastroenterology 151:440–47.e1
    [Google Scholar]
  15. 15.
    Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E et al. 2017. Whole-genome sequencing reveals breast cancers with mismatch repair deficiency. Cancer Res 77:4755–62
    [Google Scholar]
  16. 16.
    Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF 2009. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 29:1615–20
    [Google Scholar]
  17. 17.
    Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ 2017. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome. Hum. Pathol. 70:121–28
    [Google Scholar]
  18. 18.
    Espenschied CR, LaDuca H, Li S, McFarland R, Gau CL, Hampel H 2017. Multigene panel testing provides a new perspective on Lynch syndrome. J. Clin. Oncol. 35:2568–75
    [Google Scholar]
  19. 19.
    Eval. Genom. Appl. Pract. Prev. (EGAPP) Work. Group 2009. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med 11:35–41
    [Google Scholar]
  20. 20.
    Fallik D, Borrini F, Boige V, Viguier J, Jacob S et al. 2003. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738–44
    [Google Scholar]
  21. 21.
    Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC 1994. A prospective study of family history and the risk of colorectal cancer. N. Engl. J. Med. 331:1669–74
    [Google Scholar]
  22. 22.
    Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM et al. 2015. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. J. Clin. Oncol. 33:2084–91
    [Google Scholar]
  23. 23.
    Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY et al. 2012. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin. Cancer Res. 18:6531–41
    [Google Scholar]
  24. 24.
    Geurts-Giele WR, Leenen CH, Dubbink HJ, Meijssen IC, Post E et al. 2014. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. J. Pathol. 234:548–59
    [Google Scholar]
  25. 25.
    Giráldez MD, Balaguer F, Bujanda L, Cuatrecasas M, Muñoz J et al. 2010. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin. Cancer Res. 16:5402–13
    [Google Scholar]
  26. 26.
    Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE et al. 2015. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch Syndrome screening in endometrial cancers from GOG210: an NRG oncology and gynecologic oncology group study. J. Clin. Oncol. 33:4301–8
    [Google Scholar]
  27. 27.
    Gras E, Catasus L, Argüelles R, Moreno-Bueno G, Palacios J et al. 2001. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92:2829–36
    [Google Scholar]
  28. 28.
    Green RC, Parfrey PS, Woods MO, Younghusband HB 2009. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J. Natl. Cancer Inst. 101:331–40
    [Google Scholar]
  29. 29.
    Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E 2010. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur. J. Cancer 46:2788–98
    [Google Scholar]
  30. 30.
    Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F et al. 2017. MSH2 loss in primary prostate cancer. Clin. Cancer Res. 23:6863–74
    [Google Scholar]
  31. 31.
    Hall G, Clarkson A, Shi A, Langford E, Leung H et al. 2010. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology 42:409–13
    [Google Scholar]
  32. 32.
    Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K et al. 2008. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol. 26:5783–88
    [Google Scholar]
  33. 33.
    Hampel H, Pearlman R, Beightol M, Zhao W, Jones D et al. 2018. Assessment of tumor sequencing as a replacement for Lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncol 4:806–13
    [Google Scholar]
  34. 34.
    Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R et al. 2014. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 147:1308–16.e1
    [Google Scholar]
  35. 35.
    Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W et al. 2014. Prostate cancer incidence in males with Lynch syndrome. Genet. Med. 16:553–57
    [Google Scholar]
  36. 36.
    Harkness EF, Barrow E, Newton K, Green K, Clancy T et al. 2015. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. J. Med. Genet. 52:553–56
    [Google Scholar]
  37. 37.
    Heald B, Plesec T, Liu X, Pai R, Patil D et al. 2013. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center. J. Clin. Oncol. 31:1336–40
    [Google Scholar]
  38. 38.
    Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF et al. 2006. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J. Clin. 56:213–25
    [Google Scholar]
  39. 39.
    Hill AL, Sumra KK, Russell MM, Yoo J, Ko CY et al. 2015. A single institution experience in compliance with universal screening for Lynch syndrome in colorectal cancer. J. Gastrointest. Surg. 19:543–50
    [Google Scholar]
  40. 40.
    Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC et al. 2007. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 133:48–56
    [Google Scholar]
  41. 41.
    Kang SY, Park CK, Chang DK, Kim JW, Son HJ et al. 2015. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers. Int. J. Cancer 136:1568–78
    [Google Scholar]
  42. 42.
    Kastrinos F, Ojha RP, Leenen C, Alvero C, Mercado RC et al. 2016. Comparison of prediction models for Lynch syndrome among individuals with colorectal cancer. J. Natl. Cancer Inst. 108:djv308
    [Google Scholar]
  43. 43.
    Kastrinos F, Steyerberg EW, Balmana J, Mercado R, Gallinger S et al. 2013. Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut 62:272–79
    [Google Scholar]
  44. 44.
    Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S et al. 2011. The PREMM1,2,6 model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140:73–81
    [Google Scholar]
  45. 45.
    Kato A, Sato N, Sugawara T, Takahashi K, Kito M et al. 2016. Isolated loss of PMS2 immunohistochemical expression is frequently caused by heterogenous MLH1 promoter hypermethylation in Lynch syndrome screening for endometrial cancer patients. Am. J. Surg. Pathol. 40:770–76
    [Google Scholar]
  46. 46.
    Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M et al. 2011. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann. Intern. Med. 155:69–79
    [Google Scholar]
  47. 47.
    Laghi L, Malesci A. 2012. Microsatellite instability and therapeutic consequences in colorectal cancer. Dig. Dis. 30:304–9
    [Google Scholar]
  48. 48.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:2509–20
    [Google Scholar]
  49. 49.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J et al. 2000. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343:78–85
    [Google Scholar]
  50. 50.
    Lindor NM, Rabe K, Petersen GM, Haile R, Casey G et al. 2005. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293:1979–85
    [Google Scholar]
  51. 51.
    Lynch HT, de la Chapelle A 2003. Hereditary colorectal cancer. N. Engl. J. Med. 348:919–32
    [Google Scholar]
  52. 52.
    Lynch HT, Lynch JF, Lynch PM 2007. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J. Natl. Cancer Inst. 99:261–63
    [Google Scholar]
  53. 53.
    Lynch HT, Lynch PM, Pester J, Fusaro RM 1981. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch. Intern. Med. 141:607–11
    [Google Scholar]
  54. 54.
    Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V et al. 2017. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA versus guideline-based germline testing. JAMA 318:825–35
    [Google Scholar]
  55. 55.
    Mas-Moya J, Dudley B, Brand RE, Thull D, Bahary N et al. 2015. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. Hum. Pathol. 46:1616–25
    [Google Scholar]
  56. 56.
    McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ et al. 2004. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam. Cancer 3:101–7
    [Google Scholar]
  57. 57.
    McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA et al. 2016. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study. J. Clin. Oncol. 34:3062–68
    [Google Scholar]
  58. 58.
    Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H et al. 2014. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 146:643–46.e8
    [Google Scholar]
  59. 59.
    Mills AM, Sloan EA, Thomas M, Modesitt SC, Stoler MH et al. 2015. Clinicopathologic comparison of Lynch syndrome-associated and “Lynch-like” endometrial carcinomas identified on universal screening using mismatch repair protein immunohistochemistry. Am. J. Surg. Pathol. 40:155–65
    [Google Scholar]
  60. 60.
    Mork ME, You YN, Ying J, Bannon SA, Lynch PM et al. 2015. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J. Clin. Oncol. 33:3544–49
    [Google Scholar]
  61. 61.
    Mvundura M, Grosse SD, Hampel H, Palomaki GE 2010. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet. Med. 12:93–104
    [Google Scholar]
  62. 62.
    Natl. Compr. Cancer Netw 2018. NCCN Guidelines for colon cancer Version 1.2018, accessed July 24, 2018. Available at https://www.nccn.org/professionals/physician_gls
  63. 63.
    Natl. Compr. Cancer Netw 2018. NCCN Guidelines for genetic/familial high-risk assessment: colorectal Version 1.2018, accessed July 24, 2018. Available at https://www.nccn.org/professionals/physician_gls
  64. 64.
    Niu B, Ye K, Zhang Q, Lu C, Xie M et al. 2014. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30:1015–16
    [Google Scholar]
  65. 65.
    Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK et al. 2016. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2:482–90
    [Google Scholar]
  66. 66.
    Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F et al. 2018. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36:773–79
    [Google Scholar]
  67. 67.
    Pal T, Akbari MR, Sun P, Lee JH, Fulp J et al. 2012. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br. J. Cancer 107:1783–90
    [Google Scholar]
  68. 68.
    Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN 2009. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet. Med. 11:42–65
    [Google Scholar]
  69. 69.
    Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A et al. 2017. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3:464–71
    [Google Scholar]
  70. 70.
    Pearlman R, Markow M, Knight D, Chen W, Arnold CA et al. 2018. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Mod. Pathol. 31:1891–900
    [Google Scholar]
  71. 71.
    Popat S, Hubner R, Houlston RS 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23:609–18
    [Google Scholar]
  72. 72.
    Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C et al. 2014. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 5:4988
    [Google Scholar]
  73. 73.
    Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N et al. 2016. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod. Pathol. 29:1381–89
    [Google Scholar]
  74. 74.
    Roberts ME, Jackson SA, Susswein LR, Zeinomar N, Ma X et al. 2018. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet. Med. 20:1167–74
    [Google Scholar]
  75. 75.
    Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ et al. 2015. Integrative clinical genomics of advanced prostate cancer. Cell 162:454
    [Google Scholar]
  76. 76.
    Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR et al. 1997. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J. Natl. Cancer Inst. 89:1758–62
    [Google Scholar]
  77. 77.
    Rodríguez-Soler M, Pérez-Carbonell L, Guarinos C, Zapater P, Castillejo A et al. 2013. Risk of cancer in cases of suspected Lynch syndrome without germline mutation. Gastroenterology 144:926–32.e1
    [Google Scholar]
  78. 78.
    Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC 2014. Microsatellite instability detection by next generation sequencing. Clin. Chem. 60:1192–99
    [Google Scholar]
  79. 79.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R et al. 2010. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28:3219–26
    [Google Scholar]
  80. 80.
    Sargent DJ, Shi Q, Yothers G, Tejpar S, Bertagnolli MM et al. 2014. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J. Clin. Oncol. 32:3507
    [Google Scholar]
  81. 81.
    Schwark AL, Srinivasan P, Kernel Y, Shia J, Bandlamudi C et al. 2018. Pan-cancer microsatellite instability to predict for presence of Lynch syndrome. J. Clin. Oncol. 36:Suppl.LBA1509
    [Google Scholar]
  82. 82.
    Senter L. 2012. Genetic testing by cancer site: colon (nonpolyposis syndromes). Cancer J 18:334–37
    [Google Scholar]
  83. 83.
    Shaikh T, Handorf EA, Meyer JE, Hall MJ, Esnaola NF 2018. Mismatch repair deficiency testing in patients with colorectal cancer and nonadherence to testing guidelines in young adults. JAMA Oncol 4:e173580
    [Google Scholar]
  84. 84.
    Shia J. 2008. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J. Mol. Diagnostics 10:293–300
    [Google Scholar]
  85. 85.
    Shiovitz S, Copeland WK, Passarelli MN, Burnett-Hartman AN, Grady WM et al. 2014. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. Br. J. Cancer 111:598–602
    [Google Scholar]
  86. 86.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G et al. 2011. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl. Cancer Inst. 103:863–75
    [Google Scholar]
  87. 87.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS et al. 2013. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J. Clin. Oncol. 31:3664–72
    [Google Scholar]
  88. 88.
    Sourrouille I, Coulet F, Lefevre JH, Colas C, Eyries M et al. 2013. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam. Cancer 12:27–33
    [Google Scholar]
  89. 89.
    South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A 2008. The frequency of Muir-Torre syndrome among Lynch syndrome families. J. Natl. Cancer Inst. 100:277–81
    [Google Scholar]
  90. 90.
    Takeda T, Tsuji K, Banno K, Yanokura M, Kobayashi Y et al. 2018. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer. J. Gynecol. Oncol. 29:e29
    [Google Scholar]
  91. 91.
    Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M 2017. Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br. J. Cancer 117:1702–10
    [Google Scholar]
  92. 92.
    Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A et al. 2004. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96:261–68
    [Google Scholar]
  93. 93.
    Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E et al. 2009. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27:3117–25
    [Google Scholar]
  94. 94.
    Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J 2018. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7:746–56
    [Google Scholar]
  95. 95.
    Vasen HF. 2005. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Fam. Cancer 4:219–25
    [Google Scholar]
  96. 96.
    Vasen HF, Mecklin JP, Khan PM, Lynch HT 1991. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum 34:424–25
    [Google Scholar]
  97. 97.
    Vasen HF, Watson P, Mecklin JP, Lynch HT 1999. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453–56
    [Google Scholar]
  98. 98.
    Vilar E, Gruber SB. 2010. Microsatellite instability in colorectal cancer—the stable evidence. Nat. Rev. Clin. Oncol. 7:153–62
    [Google Scholar]
  99. 99.
    Vilar E, Mork ME, Cuddy A, Borras E, Bannon SA et al. 2014. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet 207:495–502
    [Google Scholar]
  100. 100.
    Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST et al. 2010. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin. Cancer Res. 16:2214–24
    [Google Scholar]
  101. 101.
    Weissman SM, Burt R, Church J, Erdman S, Hampel H et al. 2012. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J. Genet. Couns. 21:484–93
    [Google Scholar]
  102. 102.
    Win AK, Lindor NM, Jenkins MA 2013. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res 15:R27
    [Google Scholar]
  103. 103.
    Win AK, Lindor NM, Young JP, Macrae FA, Young GP et al. 2012. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J. Natl. Cancer Inst. 104:1363–72
    [Google Scholar]
  104. 104.
    Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH et al. 1999. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am. J. Hum. Genet. 65:1291–98
    [Google Scholar]
  105. 105.
    Zhang L. 2008. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J. Mol. Diagn. 10:301–7
    [Google Scholar]
/content/journals/10.1146/annurev-genom-083118-015406
Loading
/content/journals/10.1146/annurev-genom-083118-015406
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error